X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CT053 (zevorcabtagene autoleucel) is an autologous BCMA-targeted CAR T-cell product, which is being evaluated for the treatment of relapsed or refractory multiple myeloma.
Lead Product(s): Zevorcabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT053
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
CT011 is an autologous CAR T-cell product candidate against GPC3. It is currently being evaluated for the treatment of patients with GPC3-positive stage Ⅲa hepatocellular carcinoma.
Lead Product(s): CT011
Therapeutic Area: Oncology Product Name: CT011
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
CT071 is a GPRC5D inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): CT071
Therapeutic Area: Oncology Product Name: CT071
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
The collaboration aims to investigate CARsgen's investigational CT041 (satricabtagene autoleucel), a Claudin18.2 CAR T-cell product candidate, in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.
Lead Product(s): Satricabtagene Autoleucel,Claudin18.2 mRNA Vaccine
Therapeutic Area: Oncology Product Name: CT041
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 21, 2023
Details:
CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first-in-class treatment for positive solid tumors with a primary focus on gastric cancer/gastroesophageal junction cancer (GC/GEJ) and PC.
Lead Product(s): CT041
Therapeutic Area: Oncology Product Name: CT041
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
AB011 is a humanized CLDN18.2 monoclonal antibody (mAb) product that has received an investigational new drug (IND) approval from the National Medical Products Administration (NMPA) for the treatment of CLDN18.2 positive solid tumors.
Lead Product(s): AB011,Atezolizumab,Capecitabine
Therapeutic Area: Oncology Product Name: AB011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first-in-class treatment for positive solid tumors with a primary focus on gastric cancer/gastroesophageal junction cancer (GC/GEJ) and PC.
Lead Product(s): CT041
Therapeutic Area: Oncology Product Name: CT041
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Under the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of AB011 treatment arms in study. The co-funded study of AB011 in combination with atezolizumab will be conducted as part of Roche's Morpheus Platform.
Lead Product(s): Humanized Claudin18.2 Monoclonal Antibody,Atezolizumab
Therapeutic Area: Oncology Product Name: AB011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 31, 2023
Details:
AB011 is a humanized Claudin18.2 mAb product that has received an IND approval from the NMPA for the treatment of Claudin18.2 positive solid tumors. AB011 is being investigated for the treatment of Claudin18.2 positive solid tumors in China.
Lead Product(s): Humanized Claudin18.2 Monoclonal Antibody
Therapeutic Area: Oncology Product Name: AB011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Zevor-cel (CT053) is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of R/R MM. Results from the LUMMICAR-1 study show that zevor-cel, demonstrated strong and durable efficacy in patients with relapsed/refractory multiple myeloma.
Lead Product(s): Zevorcabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT053
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
